Close Menu

NEW YORK – Thermo Fisher Scientific announced yesterday a three-year, C$6 million (US$4.5 million) collaboration with Genome Canada and the Ontario Institute for Cancer Research (OICR) to develop targeted next-generation sequencing-based assays and analysis software.

Under the terms of the agreement, the partners will develop three assays, one for rapid diagnosis of pancreatic cancer, and two for targeted treatments — in prostate and breast cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sep
16

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.